Phialomustin-B reduced SOD1 aggregation in laboratory studies
Original source
Structural insights into the modulation Of SOD1 aggregation By a fungal metabolite Phialomustin-B: Therapeutic potential in ALS. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human
Related topics
Researchers identified Phialomustin-B, a fungal metabolite that binds to SOD1 and reduced formation of a toxic SOD1 intermediate in laboratory analyses. The work focused on normal SOD1 and the SOD1 A4V disease-associated mutant, and suggests Phialomustin-B could be a lead for therapies targeting some familial ALS (fALS) cases.
Why this matters
The finding is relevant to ALS linked to SOD1 mutations, but it is an early laboratory result. It does not show that Phialomustin-B improves symptoms or changes treatment for people with ALS.
Limitations and context
The report describes structural and aggregation experiments, not testing in people or evidence of clinical benefit. Further studies would be needed to establish safety, dosing and whether the compound can slow disease in relevant biological models or patients.